Responsiveness of endpoints in osteoporosis clinical trials

被引：0

作者：

Wells, G

Cranney, A

Shea, B

Tugwell, P

机构：

[1] UNIV OTTAWA, DEPT MED, OTTAWA, ON, CANADA

[2] UNIV OTTAWA, DEPT EPIDEMIOL, OTTAWA, ON, CANADA

来源：

JOURNAL OF RHEUMATOLOGY | 1997年 / 24卷 / 06期

关键词：

osteoporosis; clinical trials; outcome measures;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The usefulness of an endpoint depends in part on its responsiveness to clinically important change. From existing randomized controlled trials, the responsiveness of endpoints currently employed in osteoporosis clinical trials were examined. The responsiveness is presented as the sample size per group needed to show a statistically significant difference. The large variation found means that careful attention needs to be given to the responsiveness of the population studied when estimating the sample size.

引用

收藏

页码：1230 / 1233

页数：4

相关论文

共 14 条

[1] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

[2] VITAMIN-D(3) AND CALCIUM TO PREVENT HIP-FRACTURES IN ELDERLY WOMEN [J].

CHAPUY, MC ;

ARLOT, ME ;

DUBOEUF, F ;

BRUN, J ;

CROUZET, B ;

ARNAUD, S ;

DELMAS, PD ;

MEUNIER, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (23) :1637-1642

[3]

Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences, V2

[4] MEASURING RELEVANT CHANGE - AN EMERGING CHALLENGE IN RHEUMATOLOGIC CLINICAL-TRIALS [J].

FORTIN, PR ;

STUCKI, G ;

KATZ, JN .

ARTHRITIS AND RHEUMATISM, 1995, 38 (08) :1027-1030

[5]

Garnero P, 1996, J BONE MINER RES, V11, P1531

[6] EFFECT SIZES FOR INTERPRETING CHANGES IN HEALTH-STATUS [J].

KAZIS, LE ;

ANDERSON, JJ ;

MEENAN, RF .

MEDICAL CARE, 1989, 27 (03) :S178-S189

[7] EFFECT OF ORAL ALENDRONATE ON BONE-MINERAL DENSITY AND THE INCIDENCE OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS [J].

LIBERMAN, UA ;

WEISS, SR ;

BROLL, J ;

MINNE, HW ;

QUAN, H ;

BELL, NH ;

RODRIGUEZPORTALES, J ;

DOWNS, RW ;

DEQUEKER, J ;

FAVUS, M ;

SEEMAN, E ;

RECKER, RR ;

CAPIZZI, T ;

SANTORA, AC ;

LOMBARDI, A ;

SHAH, RV ;

HIRSCH, LJ ;

KARPF, DB .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (22) :1437-1443

[8] TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH TRANSDERMAL ESTROGEN [J].

LUFKIN, EG ;

WAHNER, HW ;

OFALLON, WM ;

HODGSON, SF ;

KOTOWICZ, MA ;

LANE, AW ;

JUDD, HL ;

CAPLAN, RH ;

RIGGS, BL .

ANNALS OF INTERNAL MEDICINE, 1992, 117 (01) :1-9

[9] ANALGESIC EFFECT OF SALMON-CALCITONIN IN OSTEOPOROTIC VERTEBRAL FRACTURES - A DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL-STUDY [J].

LYRITIS, GP ;

TSAKALAKOS, N ;

MAGIASIS, B ;

KARACHALIOS, T ;

YIATZIDES, A ;

TSEKOURA, M .

CALCIFIED TISSUE INTERNATIONAL, 1991, 49 (06) :369-372

[10] REVERSAL OF POSTMENOPAUSAL VERTEBRAL BONE LOSS BY ESTROGEN AND PROGESTOGEN - A DOUBLE-BLIND PLACEBO CONTROLLED-STUDY [J].

MUNKJENSEN, N ;

NIELSEN, SP ;

OBEL, EB ;

ERIKSEN, PB .

BRITISH MEDICAL JOURNAL, 1988, 296 (6630) :1150-1152